title: Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model.
abstract: OBJECTIVE
  To evaluate the antitumor effects of miriplatin-lipidol suspension and emulsion.
  
  
  METHODS
  Fifty rabbits with VX2 liver tumors were randomly assigned to ten groups. Then, we prepared four types of mixtures: a suspension of lipiodol and miriplatin (ML), an emulsion of miriplatin dissolved with lipiodol and contrast medium (MLC) or saline (MLS), and saline alone (S). Ratios between lipiodol and contrast medium/saline volumes were 1:1/4, 1:1/2, 1:1, and 1:2 respectively. We used the same dose of miriplatin (2 mg/kg) and lipiodol (0.1 ml/kg) in each emulsion and suspension group. After intra-arterial infusion, the tumor growth rate was calculated, and sequential change of the plasma platinum concentration, the platinum concentration in the tumor and in surrounding normal liver tissue was also measured.
  
  
  RESULTS
  Among the ten groups, the tumor growth rate was lower in MLC and MLS groups, and the difference between tumor treated with MLS emulsion (ratio 1:1/2) and ML suspension was significant (p = 0.02). The platinum concentration in the normal liver tissue was lower in MLS and MLC groups than in the ML group, and that in the tumor was higher in the MLS and MLC emulsion (ratio 1:1/2) groups.
  
  
  CONCLUSIONS
  We suggest that miriplatin-lipiodol emulsion may be more effective than suspension.
authors.affiliation: Department of Radiology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu City, Shiga, 520-2192, Japan, tomozawa@belle.shiga-med.ac.jp.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Tomozawa
authors.forename: Norihisa
authors.initials: N
authors.lastname: Nitta
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohta
authors.forename: Hideji
authors.initials: H
authors.lastname: Otani
authors.forename: Shobu
authors.initials: S
authors.lastname: Watanabe
authors.forename: Akinaga
authors.initials: A
authors.lastname: Sonoda
authors.forename: Keiko
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Ayumi
authors.initials: A
authors.lastname: Nitta-Seko
authors.forename: Masashi
authors.initials: M
authors.lastname: Takahashi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Murata
mesh_terms: D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage / Q000494:pharmacology; D004195:Disease Models, Animal; D004655:Emulsions; D004998:Ethiodized Oil / Q000008:administration & dosage / Q000494:pharmacology*; D007261:Infusions, Intra-Arterial; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits; D011897:Random Allocation; D012965:Sodium Chloride / Q000008:administration & dosage / Q000494:pharmacology; D013535:Suspensions
chemical_list: D003287:Contrast Media; D004655:Emulsions; D009944:Organoplatinum Compounds; D013535:Suspensions; D012965:Sodium Chloride; C406530:miriplatin; D004998:Ethiodized Oil